Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned an average rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.89.

A number of research firms have commented on YMAB. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price for the company. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in YMAB. Bank of New York Mellon Corp boosted its position in shares of Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after acquiring an additional 3,589 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after acquiring an additional 2,760 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Y-mAbs Therapeutics during the second quarter worth approximately $297,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $6.18 on Friday. Y-mAbs Therapeutics has a 52-week low of $6.01 and a 52-week high of $20.90. The firm has a market capitalization of $276.80 million, a PE ratio of -11.44 and a beta of 0.69. The company’s fifty day moving average price is $9.60 and its two-hundred day moving average price is $11.96.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same quarter last year, the firm posted ($0.18) EPS. Analysts predict that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.